U.S. allocates $3.2 billion for COVID-19 pills and other viruses’ treatments

 

 

On Thursday, at a White House briefing, Dr. Anthony Fauci, the country’s leading infectious diseases expert said that a new program by the U.S. will invest $3.2 billion to accelerate the process of developing pills that can treat viruses such as COVID-19 and many more dangerous viruses.

 

He mentioned that there were few treatments for many viruses that have the potential of developing into a pandemic. It would be good to be better prepared in the future if viruses such as Ebola, Dengue, West Nile or Middle East respiratory syndrome become widespread. But he reiterated that vaccines were the “centerpiece of our arsenal.”

 

To date, the U.S. has allowed the use of remdesivir, an anti-viral drug to treat COVID-19. It has also approved emergency use of three antibody combinations that makes the body’s immune system fight against the virus. These drugs have to be taken under medical supervision. However, health experts feel that a pill that can be taken patients who exhibit initial symptoms would be both convenient and helpful.

 

Initial research to make pills by drug makers has started but results will take several months. By disbursing additional funds, the government hopes to accelerate the development and manufacturing process of the private pharma involved in this endeavor.

 

Merck has been experimenting with a drug called molnupiravir. Large study results are expected by fall. Initial results indicate that the drug could reduce the risk of hospitalization, if used early in the infectious stage. It works by preventing the coronavirus from replicating easily. However, it had no effect on those who had already been hospitalized due to COVID-19.

 

Merck is not the only pharmaceutical company to research on antiviral pills. Pfizer, Roche, and AstraZeneca are three other large companies that are conducted research and looking to manufacture a pop in pill.

 

The latest round of funding by the US government for antiviral pills is not only expected to accelerate research but also act as a stockpile as scientists have said that there’s no timeline on when COVID-19 will no longer be a part of the infections that affect humans. However, they hope that vaccines, pills, and booster shots will weaken the virus to make it more manageable in future.

Photo-

Author NIAID

Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>